Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.

Ann-Kathrin Hartmann,Joschka Bartneck,Jonas Pielenhofer,Sophie Luise Meiser,Danielle Arnold-Schild,Matthias Klein,Michael Stassen,Hansjörg Schild,Sabine Muth,Hans Christian Probst,Peter Langguth,Stephan Grabbe,Markus P Radsak

Frontiers in immunology（2023）

引用 0|浏览4

暂无评分

摘要

Taken together, the described optimized transcutaneous vaccination method leads to the generation of a strong cellular immune response enabling the effective control of tumor growth and has the potential for clinical development as a novel non-invasive vaccination method for peptide-based cancer vaccines in humans.

查看译文

关键词

transcutaneous immunization,tumor rejection,dithranol-imiquimod-based

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要